[1]
Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. The Journal of pathology. 2019 Apr:247(5):574-588. doi: 10.1002/path.5229. Epub 2019 Feb 20
[PubMed PMID: 30584801]
[2]
Baglietto L, Jenkins MA, Severi G, Giles GG, Bishop DT, Boyle P, Hopper JL. Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. Journal of clinical epidemiology. 2006 Feb:59(2):114-24
[PubMed PMID: 16426946]
Level 1 (high-level) evidence
[3]
PDQ Cancer Genetics Editorial Board. Genetics of Colorectal Cancer (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002:():
[PubMed PMID: 26389505]
Level 3 (low-level) evidence
[4]
Kastrinos F, Samadder NJ, Burt RW. Use of Family History and Genetic Testing to Determine Risk of Colorectal Cancer. Gastroenterology. 2020 Jan:158(2):389-403. doi: 10.1053/j.gastro.2019.11.029. Epub 2019 Nov 21
[PubMed PMID: 31759928]
[5]
Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, Buchanan DD, Clendenning M, Rosty C, Ahnen DJ, Thibodeau SN, Casey G, Gallinger S, Le Marchand L, Haile RW, Potter JD, Zheng Y, Lindor NM, Newcomb PA, Hopper JL, MacInnis RJ. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017 Mar:26(3):404-412. doi: 10.1158/1055-9965.EPI-16-0693. Epub 2016 Oct 31
[PubMed PMID: 27799157]
Level 3 (low-level) evidence
[6]
Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frébourg T, Sobol H, Lasset C, Bonaïti-Pellié C, French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011 Jun 8:305(22):2304-10. doi: 10.1001/jama.2011.743. Epub
[PubMed PMID: 21642682]
[7]
Porkka N, Lahtinen L, Ahtiainen M, Böhm JP, Kuopio T, Eldfors S, Mecklin JP, Seppälä TT, Peltomäki P. Epidemiological, clinical and molecular characterization of Lynch-like syndrome: A population-based study. International journal of cancer. 2019 Jul 1:145(1):87-98. doi: 10.1002/ijc.32085. Epub 2019 Jan 7
[PubMed PMID: 30575961]
Level 2 (mid-level) evidence
[8]
Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M, Kloor M, Büttner R, Verwiel ET, van Krieken JH, Nagtegaal ID, Goossens M, van der Post RS, Niessen RC, Sijmons RH, Kluijt I, Hogervorst FB, Leter EM, Gille JJ, Aalfs CM, Redeker EJ, Hes FJ, Tops CM, van Nesselrooij BP, van Gijn ME, Gómez García EB, Eccles DM, Bunyan DJ, Syngal S, Stoffel EM, Culver JO, Palomares MR, Graham T, Velsher L, Papp J, Oláh E, Chan TL, Leung SY, van Kessel AG, Kiemeney LA, Hoogerbrugge N, Ligtenberg MJ. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. The Lancet. Oncology. 2011 Jan:12(1):49-55. doi: 10.1016/S1470-2045(10)70265-5. Epub 2010 Dec 8
[PubMed PMID: 21145788]
[9]
Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, Purcell JU, Hanson NB, Leppig KA, Lim J, Cappel MA. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genetics in medicine : official journal of the American College of Medical Genetics. 2014 Sep:16(9):711-6. doi: 10.1038/gim.2014.19. Epub 2014 Mar 6
[PubMed PMID: 24603434]
[10]
Hu XR, Xu C, Kang Y, Wang T, Zhang Y, Yang XH. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers]. Zhonghua bing li xue za zhi = Chinese journal of pathology. 2018 Nov 8:47(11):827-833. doi: 10.3760/cma.j.issn.0529-5807.2018.11.003. Epub
[PubMed PMID: 30423605]
[11]
Karstensen JG, Burisch J, Pommergaard HC, Aalling L, Højen H, Jespersen N, Schmidt PN, Bülow S. Colorectal Cancer in Individuals With Familial Adenomatous Polyposis, Based on Analysis of the Danish Polyposis Registry. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2019 Oct:17(11):2294-2300.e1. doi: 10.1016/j.cgh.2019.02.008. Epub 2019 Feb 8
[PubMed PMID: 30743005]
[12]
Poylin VY, Shaffer VO, Felder SI, Goldstein LE, Goldberg JE, Kalady MF, Lightner AL, Feingold DL, Paquette IM, Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Adenomatous Polyposis Syndromes. Diseases of the colon and rectum. 2024 Feb 1:67(2):213-227. doi: 10.1097/DCR.0000000000003072. Epub 2023 Sep 8
[PubMed PMID: 37682806]
Level 1 (high-level) evidence
[13]
Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet (London, England). 1989 Sep 30:2(8666):783-5
[PubMed PMID: 2571019]
[14]
Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Familial cancer. 2003:2(1):43-55
[PubMed PMID: 14574166]
[15]
Yang J, Gurudu SR, Koptiuch C, Agrawal D, Buxbaum JL, Abbas Fehmi SM, Fishman DS, Khashab MA, Jamil LH, Jue TL, Law JK, Lee JK, Naveed M, Qumseya BJ, Sawhney MS, Thosani N, Wani SB, Samadder NJ. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointestinal endoscopy. 2020 May:91(5):963-982.e2. doi: 10.1016/j.gie.2020.01.028. Epub 2020 Mar 10
[PubMed PMID: 32169282]
[16]
Forkosh E, Bergel M, Hatchell KE, Nielsen SM, Heald B, Benson AA, Friedman E, Esplin ED, Katz LH. Ashkenazi Jewish and Other White APC I1307K Carriers Are at Higher Risk for Multiple Cancers. Cancers. 2022 Nov 29:14(23):. doi: 10.3390/cancers14235875. Epub 2022 Nov 29
[PubMed PMID: 36497357]
[17]
Valle L, Katz LH, Latchford A, Mur P, Moreno V, Frayling IM, Heald B, Capellá G, InSiGHT Council. Position statement of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) on APC I1307K and cancer risk. Journal of medical genetics. 2023 Nov:60(11):1035-1043. doi: 10.1136/jmg-2022-108984. Epub 2023 Apr 19
[PubMed PMID: 37076288]
[18]
Sokic-Milutinovic A. Appropriate Management of Attenuated Familial Adenomatous Polyposis: Report of a Case and Review of the Literature. Digestive diseases (Basel, Switzerland). 2019:37(5):400-405. doi: 10.1159/000497207. Epub 2019 Mar 5
[PubMed PMID: 30836352]
Level 3 (low-level) evidence
[19]
Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, Maher ER, Möslein G, Vasen HF, Coaker J, Phillips RK, Bülow S, Mathers JC, International CAPP consortium. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer prevention research (Philadelphia, Pa.). 2011 May:4(5):655-65. doi: 10.1158/1940-6207.CAPR-11-0106. Epub
[PubMed PMID: 21543343]
Level 1 (high-level) evidence
[20]
Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with familial adenomatous polyposis. Diseases of the colon and rectum. 2000 Mar:43(3):363-9
[PubMed PMID: 10733118]
[21]
Buecher B. Colorectal adenomatous polyposis syndromes: Genetic determinism, clinical presentation and recommendations for care. Bulletin du cancer. 2016 Feb:103(2):199-209. doi: 10.1016/j.bulcan.2015.10.019. Epub 2016 Jan 19
[PubMed PMID: 26805944]
[22]
Velter C, Caussade P, Fricker JP, Cribier B. [Muir-Torre syndrome and Turcot syndrome]. Annales de dermatologie et de venereologie. 2017 Aug-Sep:144(8-9):525-529. doi: 10.1016/j.annder.2017.01.017. Epub 2017 Feb 27
[PubMed PMID: 28256262]
[23]
Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP. Inherited variants of MYH associated with somatic G:C--}T:A mutations in colorectal tumors. Nature genetics. 2002 Feb:30(2):227-32
[PubMed PMID: 11818965]
[24]
Sutcliffe EG, Bartenbaker Thompson A, Stettner AR, Marshall ML, Roberts ME, Susswein LR, Wang Y, Klein RT, Hruska KS, Solomon BD. Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis. Familial cancer. 2019 Apr:18(2):203-209. doi: 10.1007/s10689-018-00116-2. Epub
[PubMed PMID: 30604180]
[25]
Kantor M, Sobrado J, Patel S, Eiseler S, Ochner C. Hereditary Colorectal Tumors: A Literature Review on MUTYH-Associated Polyposis. Gastroenterology research and practice. 2017:2017():8693182. doi: 10.1155/2017/8693182. Epub 2017 Sep 25
[PubMed PMID: 29147111]
[26]
Bikhchandani M, Amersi F, Hendifar A, Gangi A, Osipov A, Zaghiyan K, Atkins K, Cho M, Aguirre F, Hazelett D, Alvarez R, Zhou L, Hitchins M, Gong J. POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval. Genes. 2023 May 8:14(5):. doi: 10.3390/genes14051054. Epub 2023 May 8
[PubMed PMID: 37239414]
[27]
Bellido F, Pineda M, Aiza G, Valdés-Mas R, Navarro M, Puente DA, Pons T, González S, Iglesias S, Darder E, Piñol V, Soto JL, Valencia A, Blanco I, Urioste M, Brunet J, Lázaro C, Capellá G, Puente XS, Valle L. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genetics in medicine : official journal of the American College of Medical Genetics. 2016 Apr:18(4):325-32. doi: 10.1038/gim.2015.75. Epub 2015 Jul 2
[PubMed PMID: 26133394]
Level 3 (low-level) evidence
[28]
Jaeger E, Leedham S, Lewis A, Segditsas S, Becker M, Cuadrado PR, Davis H, Kaur K, Heinimann K, Howarth K, HMPS Collaboration, East J, Taylor J, Thomas H, Tomlinson I. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nature genetics. 2012 May 6:44(6):699-703. doi: 10.1038/ng.2263. Epub 2012 May 6
[PubMed PMID: 22561515]
[29]
Mankaney G, Rouphael C, Burke CA. Serrated Polyposis Syndrome. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020 Apr:18(4):777-779. doi: 10.1016/j.cgh.2019.09.006. Epub 2019 Sep 11
[PubMed PMID: 31520728]
[30]
Rosty C, Brosens LAA. Pathology of Gastrointestinal Polyposis Disorders. Gastroenterology clinics of North America. 2024 Mar:53(1):179-200. doi: 10.1016/j.gtc.2023.09.006. Epub 2023 Oct 20
[PubMed PMID: 38280747]
[31]
Viel A, Bruselles A, Meccia E, Fornasarig M, Quaia M, Canzonieri V, Policicchio E, Urso ED, Agostini M, Genuardi M, Lucci-Cordisco E, Venesio T, Martayan A, Diodoro MG, Sanchez-Mete L, Stigliano V, Mazzei F, Grasso F, Giuliani A, Baiocchi M, Maestro R, Giannini G, Tartaglia M, Alexandrov LB, Bignami M. A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. EBioMedicine. 2017 Jun:20():39-49. doi: 10.1016/j.ebiom.2017.04.022. Epub 2017 Apr 13
[PubMed PMID: 28551381]
[32]
Gupta V, East JE. Optimal Endoscopic Treatment and Surveillance of Serrated Polyps. Gut and liver. 2020 Jul 15:14(4):423-429. doi: 10.5009/gnl19202. Epub
[PubMed PMID: 31581390]
[33]
Latchford AR, Neale K, Phillips RK, Clark SK. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. Diseases of the colon and rectum. 2012 Oct:55(10):1038-43. doi: 10.1097/DCR.0b013e31826278b3. Epub
[PubMed PMID: 22965402]
[34]
Matsumoto T, Umeno J, Jimbo K, Arai M, Iwama I, Kashida H, Kudo T, Koizumi K, Sato Y, Sekine S, Tanaka S, Tanakaya K, Tamura K, Hirata K, Fukahori S, Esaki M, Ishikawa H, Iwama T, Okazaki Y, Saito Y, Matsuura N, Mutoh M, Tomita N, Akiyama T, Yamamoto T, Ishida H, Nakayama Y. Clinical Guidelines for Diagnosis and Management of Juvenile Polyposis Syndrome in Children and Adults-Secondary Publication. Journal of the anus, rectum and colon. 2023:7(2):115-125. doi: 10.23922/jarc.2023-002. Epub 2023 Apr 25
[PubMed PMID: 37113581]
[35]
Gilad O, Rosner G, Fliss-Isakov N, Aharon-Kaspi S, Strul H, Gluck N, Kariv R. Clinical and Histologic Overlap and Distinction Among Various Hamartomatous Polyposis Syndromes. Clinical and translational gastroenterology. 2019 May 22:10(5):1-9. doi: 10.14309/ctg.0000000000000035. Epub
[PubMed PMID: 31107726]
[36]
McDonald NM, Ramos GP, Sweetser S. SMAD4 mutation and the combined juvenile polyposis and hereditary hemorrhage telangiectasia syndrome: a single center experience. International journal of colorectal disease. 2020 Oct:35(10):1963-1965. doi: 10.1007/s00384-020-03670-3. Epub 2020 Jun 15
[PubMed PMID: 32556653]
[37]
Spoto CPE, Gullo I, Carneiro F, Montgomery EA, Brosens LAA. Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing. Seminars in diagnostic pathology. 2018 May:35(3):170-183. doi: 10.1053/j.semdp.2018.01.004. Epub 2018 Jan 31
[PubMed PMID: 29397239]
[38]
Sengupta S, Bose S. Peutz-Jeghers Syndrome. The New England journal of medicine. 2019 Jan 31:380(5):472. doi: 10.1056/NEJMicm1806623. Epub
[PubMed PMID: 30699321]
[39]
Chen HY, Jin XW, Li BR, Zhu M, Li J, Mao GP, Zhang YF, Ning SB. Cancer risk in patients with Peutz-Jeghers syndrome: A retrospective cohort study of 336 cases. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2017 Jun:39(6):1010428317705131. doi: 10.1177/1010428317705131. Epub
[PubMed PMID: 28653895]
Level 2 (mid-level) evidence
[40]
Korsse SE, Harinck F, van Lier MG, Biermann K, Offerhaus GJ, Krak N, Looman CW, van Veelen W, Kuipers EJ, Wagner A, Dekker E, Mathus-Vliegen EM, Fockens P, van Leerdam ME, Bruno MJ. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. Journal of medical genetics. 2013 Jan:50(1):59-64. doi: 10.1136/jmedgenet-2012-101277. Epub
[PubMed PMID: 23240097]
[41]
Yamamoto H, Sakamoto H, Kumagai H, Abe T, Ishiguro S, Uchida K, Kawasaki Y, Saida Y, Sano Y, Takeuchi Y, Tajika M, Nakajima T, Banno K, Funasaka Y, Hori S, Yamaguchi T, Yoshida T, Ishikawa H, Iwama T, Okazaki Y, Saito Y, Matsuura N, Mutoh M, Tomita N, Akiyama T, Yamamoto T, Ishida H, Nakayama Y. Clinical Guidelines for Diagnosis and Management of Peutz-Jeghers Syndrome in Children and Adults. Digestion. 2023:104(5):335-347. doi: 10.1159/000529799. Epub 2023 Apr 13
[PubMed PMID: 37054692]
[42]
Yauy K, Imbert-Bouteille M, Bubien V, Lindet-Bourgeois C, Rathat G, Perrochia H, MacGrogan G, Longy M, Bessis D, Tinat J, Baert-Desurmont S, Blanluet M, Perre PV, Baudry K, Pujol P, Corsini C. Ovarian Clear Cell Carcinoma in Cowden Syndrome. Journal of the National Comprehensive Cancer Network : JNCCN. 2019 Jan:17(1):7-11. doi: 10.6004/jnccn.2018.7065. Epub
[PubMed PMID: 30659124]
[43]
Eissing M, Ripken L, Schreibelt G, Westdorp H, Ligtenberg M, Netea-Maier R, Netea MG, de Vries IJM, Hoogerbrugge N. PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Translational oncology. 2019 Feb:12(2):361-367. doi: 10.1016/j.tranon.2018.11.003. Epub 2018 Nov 30
[PubMed PMID: 30504085]
[44]
Heald B, Burke CA, Kalady M, Eng C. ACG Guidelines on Management of PTEN-Hamartoma Tumor Syndrome: Does the Evidence Support so Much so Young? The American journal of gastroenterology. 2015 Dec:110(12):1733-4. doi: 10.1038/ajg.2015.368. Epub
[PubMed PMID: 26673503]
[45]
Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N, PHTS Guideline Development Group, European Reference Network GENTURIS. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European journal of human genetics : EJHG. 2020 Oct:28(10):1387-1393. doi: 10.1038/s41431-020-0651-7. Epub 2020 Jun 12
[PubMed PMID: 32533092]
[46]
Yehia L, Ngeow J, Eng C. PTEN-opathies: from biological insights to evidence-based precision medicine. The Journal of clinical investigation. 2019 Feb 1:129(2):452-464. doi: 10.1172/JCI121277. Epub 2019 Jan 7
[PubMed PMID: 30614812]
[47]
Kupfer SS, Gupta S, Weitzel JN, Samadder J. AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary. Gastroenterology. 2020 Aug:159(2):760-764. doi: 10.1053/j.gastro.2020.03.086. Epub 2020 Apr 23
[PubMed PMID: 32335146]
Level 3 (low-level) evidence
[48]
Pan W, Lu K, Wang W, Yao J, Hou Y. PALB2 as a potential prognostic biomarker for colorectal cancer. Computational biology and chemistry. 2020 May 20:87():107289. doi: 10.1016/j.compbiolchem.2020.107289. Epub 2020 May 20
[PubMed PMID: 32497983]
[49]
MacFarland SP, Zelley K, Long JM, McKenna D, Mamula P, Domchek SM, Nathanson KL, Brodeur GM, Rustgi AK, Katona BW, Maxwell KN. Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. Gastroenterology. 2019 Jan:156(1):273-274. doi: 10.1053/j.gastro.2018.09.036. Epub 2018 Sep 19
[PubMed PMID: 30243621]
[50]
Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016 Dec 1:122(23):3673-3681. doi: 10.1002/cncr.30248. Epub 2016 Aug 6
[PubMed PMID: 27496084]
[51]
PDQ Cancer Genetics Editorial Board. Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002:():
[PubMed PMID: 38630970]
Level 3 (low-level) evidence
[52]
Tacheci I, Repak R, Podhola M, Benesova L, Cyrany J, Bures J, Kohoutova D. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) - A Helicobacter-opposite point. Best practice & research. Clinical gastroenterology. 2021 Mar-Apr:50-51():101728. doi: 10.1016/j.bpg.2021.101728. Epub 2021 Feb 15
[PubMed PMID: 33975682]
[53]
Hoskins B, Wasuwanich P, Scheimann AO, Karnsakul W. Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis. World journal of gastrointestinal oncology. 2021 Sep 15:13(9):1121-1131. doi: 10.4251/wjgo.v13.i9.1121. Epub
[PubMed PMID: 34616517]
[54]
Birch RJ, Peckham D, Wood HM, Quirke P, Konstant-Hambling R, Brownlee K, Cosgriff R, Consortium GER, Burr N, Downing A. The risk of colorectal cancer in individuals with mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene: An English population-based study. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2023 May:22(3):499-504. doi: 10.1016/j.jcf.2022.10.001. Epub 2022 Oct 15
[PubMed PMID: 36253274]
[55]
Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, Cystic Fibrosis Colorectal Cancer Screening Task Force. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology. 2018 Feb:154(3):736-745.e14. doi: 10.1053/j.gastro.2017.12.012. Epub 2017 Dec 29
[PubMed PMID: 29289528]
Level 3 (low-level) evidence
[56]
Win AK, Cleary SP, Dowty JG, Baron JA, Young JP, Buchanan DD, Southey MC, Burnett T, Parfrey PS, Green RC, Le Marchand L, Newcomb PA, Haile RW, Lindor NM, Hopper JL, Gallinger S, Jenkins MA. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. International journal of cancer. 2011 Nov 1:129(9):2256-62. doi: 10.1002/ijc.25870. Epub 2011 Apr 8
[PubMed PMID: 21171015]
[57]
Xiang HP, Geng XP, Ge WW, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. European journal of cancer (Oxford, England : 1990). 2011 Nov:47(17):2546-51. doi: 10.1016/j.ejca.2011.03.025. Epub 2011 Jul 30
[PubMed PMID: 21807500]
Level 1 (high-level) evidence
[58]
Sriramulu S, Ramachandran M, Subramanian S, Kannan R, Gopinath M, Sollano J, Bissi L, Banerjee A, Marotta F, Pathak S. A review on role of ATM gene in hereditary transfer of colorectal cancer. Acta bio-medica : Atenei Parmensis. 2019 Jan 15:89(4):463-469. doi: 10.23750/abm.v89i4.6095. Epub 2019 Jan 15
[PubMed PMID: 30657113]
[59]
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: a cancer journal for clinicians. 2024 Jan-Feb:74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17
[PubMed PMID: 38230766]
[60]
Cronin KA, Scott S, Firth AU, Sung H, Henley SJ, Sherman RL, Siegel RL, Anderson RN, Kohler BA, Benard VB, Negoita S, Wiggins C, Cance WG, Jemal A. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022 Dec 15:128(24):4251-4284. doi: 10.1002/cncr.34479. Epub 2022 Oct 27
[PubMed PMID: 36301149]
[61]
Venugopal A, Stoffel EM. Colorectal Cancer in Young Adults. Current treatment options in gastroenterology. 2019 Mar:17(1):89-98. doi: 10.1007/s11938-019-00219-4. Epub
[PubMed PMID: 30712157]
[62]
Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, Ponz de Leon M, Rustgi AK, Castells A, EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012 Oct 17:308(15):1555-65. doi: 10.1001/jama.2012.13088. Epub
[PubMed PMID: 23073952]
[63]
Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Yen T, Stanich PP, Axell L, Patel SG. APC-Associated Polyposis Conditions. GeneReviews(®). 1993:():
[PubMed PMID: 20301519]
[65]
Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer research. 1985 Apr:45(4):1437-43
[PubMed PMID: 2983882]
[66]
Chen JJ, Wang AQ, Chen QQ. DNA methylation assay for colorectal carcinoma. Cancer biology & medicine. 2017 Feb:14(1):42-49. doi: 10.20892/j.issn.2095-3941.2016.0082. Epub
[PubMed PMID: 28443202]
[67]
Gupta R, Sinha S, Paul RN. The impact of microsatellite stability status in colorectal cancer. Current problems in cancer. 2018 Nov:42(6):548-559. doi: 10.1016/j.currproblcancer.2018.06.010. Epub 2018 Jul 18
[PubMed PMID: 30119911]
[68]
De' Angelis GL, Bottarelli L, Azzoni C, De' Angelis N, Leandro G, Di Mario F, Gaiani F, Negri F. Microsatellite instability in colorectal cancer. Acta bio-medica : Atenei Parmensis. 2018 Dec 17:89(9-S):97-101. doi: 10.23750/abm.v89i9-S.7960. Epub 2018 Dec 17
[PubMed PMID: 30561401]
[69]
Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, Lindblom A, Macrae F, Blanco I, Sijmons RH, Jeffries J, Vasen HFA, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen JT, Jenkins MA, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Valentin MD, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Moeslein G, Sampson JR, Capella G, Mallorca Group. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018 Jul:67(7):1306-1316. doi: 10.1136/gutjnl-2017-314057. Epub 2017 Jul 28
[PubMed PMID: 28754778]
[70]
Pearlman R, Frankel WL, Swanson BJ, Jones D, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Prior TW, Haut M, Kalady MF, Heald B, Paquette I, Draper DJ, Brell JM, Mahesh S, Weeman K, Bastola S, Zangmeister J, Gowda A, Kencana F, Malcolm A, Liu Y, Cole S, Bane C, Li C, Rehmus E, Pritchard CC, Shirts BH, Jacobson A, Cummings SA, de la Chapelle A, Hampel H. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. JCO precision oncology. 2021:5():. pii: PO.20.00525. doi: 10.1200/PO.20.00525. Epub 2021 May 5
[PubMed PMID: 34250417]
[71]
Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World journal of clinical cases. 2018 Dec 6:6(15):869-881. doi: 10.12998/wjcc.v6.i15.869. Epub
[PubMed PMID: 30568941]
Level 3 (low-level) evidence
[72]
Ballester V, Rashtak S, Boardman L. Clinical and molecular features of young-onset colorectal cancer. World journal of gastroenterology. 2016 Feb 7:22(5):1736-44. doi: 10.3748/wjg.v22.i5.1736. Epub
[PubMed PMID: 26855533]
[73]
Li H, Zhang L, Jiang Q, Shi Z, Tong H. Identification a nonsense mutation of APC gene in Chinese patients with familial adenomatous polyposis. Experimental and therapeutic medicine. 2017 Apr:13(4):1495-1499. doi: 10.3892/etm.2017.4122. Epub 2017 Feb 14
[PubMed PMID: 28413499]
[74]
Abbaszadegan MR, Moghbeli M. Genetic and molecular origins of colorectal Cancer among the Iranians: an update. Diagnostic pathology. 2018 Dec 22:13(1):97. doi: 10.1186/s13000-018-0774-0. Epub 2018 Dec 22
[PubMed PMID: 30579343]
[75]
Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. The New England journal of medicine. 2009 Dec 17:361(25):2449-60. doi: 10.1056/NEJMra0804588. Epub
[PubMed PMID: 20018966]
[76]
Issa JP. CpG island methylator phenotype in cancer. Nature reviews. Cancer. 2004 Dec:4(12):988-93. doi: 10.1038/nrc1507. Epub
[PubMed PMID: 15573120]
[77]
Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS, Fenoglio-Preiser CM, Potter JD. Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002 Jul:11(7):622-9
[PubMed PMID: 12101109]
[78]
Moufid FZ, Bouguenouch L, El Bouchikhi I, Chbani L, Iraqui Houssaini M, Sekal M, Belhassan K, Bennani B, Ouldim K. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence. Genetic testing and molecular biomarkers. 2018 Aug:22(8):492-497. doi: 10.1089/gtmb.2018.0067. Epub 2018 Jul 25
[PubMed PMID: 30044143]
[79]
González ML, Causada-Calo N, Santino JP, Dominguez-Valentin M, Ferro FA, Sammartino I, Kalfayan PG, Verzura MA, Piñero TA, Cajal AR, Pavicic W, Vaccaro C. Universal determination of microsatellite instability using BAT26 as a single marker in an Argentine colorectal cancer cohort. Familial cancer. 2018 Jul:17(3):395-402. doi: 10.1007/s10689-017-0052-4. Epub
[PubMed PMID: 29128931]
[80]
Hatfield E, Green JS, Woods MO, Warden G, Parfrey PS. Impact of colonoscopic screening in Familial Colorectal Cancer Type X. Molecular genetics & genomic medicine. 2018 Nov:6(6):1021-1030. doi: 10.1002/mgg3.478. Epub 2018 Oct 9
[PubMed PMID: 30300963]
[81]
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK, US Multi-Society Task Force on Colorectal Cancer. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014 Aug:147(2):502-26. doi: 10.1053/j.gastro.2014.04.001. Epub
[PubMed PMID: 25043945]
Level 3 (low-level) evidence
[82]
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK, American Society for Gastrointestinal Endoscopy. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal endoscopy. 2014 Aug:80(2):197-220. doi: 10.1016/j.gie.2014.06.006. Epub
[PubMed PMID: 25034835]
Level 3 (low-level) evidence
[83]
Arakawa K, Hata K, Kawai K, Tanaka T, Nishikawa T, Sasaki K, Shuno Y, Kaneko M, Hiyoshi M, Emoto S, Murono K, Nozawa H. Predictors for High Microsatellite Instability in Patients with Colorectal Cancer Fulfilling the Revised Bethesda Guidelines. Anticancer research. 2018 Aug:38(8):4871-4876. doi: 10.21873/anticanres.12800. Epub
[PubMed PMID: 30061262]
[84]
Coughlin SE, Heald B, Clark DF, Nielsen SM, Hatchell KE, Esplin ED, Katona BW. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer. JCO precision oncology. 2022 Nov:6():e2200517. doi: 10.1200/PO.22.00517. Epub
[PubMed PMID: 36370464]
[85]
Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. European journal of cancer (Oxford, England : 1990). 2022 Nov:175():136-157. doi: 10.1016/j.ejca.2022.07.020. Epub 2022 Sep 14
[PubMed PMID: 36115290]
[86]
Morin PJ. Colorectal cancer: the APC-lncRNA link. The Journal of clinical investigation. 2019 Feb 1:129(2):503-505. doi: 10.1172/JCI125985. Epub 2019 Jan 14
[PubMed PMID: 30640173]
[87]
Trotter J, Pantel AR, Teo BK, Escorcia FE, Li T, Pryma DA, Taunk NK. Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT. Advances in radiation oncology. 2023 Sep-Oct:8(5):101212. doi: 10.1016/j.adro.2023.101212. Epub 2023 Mar 27
[PubMed PMID: 37197709]
Level 3 (low-level) evidence
[88]
Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ, Hartford NM, Oliva E, Chung DC. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer. 2018 Aug 1:124(15):3145-3153. doi: 10.1002/cncr.31534. Epub 2018 May 11
[PubMed PMID: 29750335]
[89]
Zhang J, Li Z, Huang X, Ye J. [Clinical and molecular characteristics of a child with familial adenomatous polyposis]. Zhonghua er ke za zhi = Chinese journal of pediatrics. 2016 Mar:54(3):205-8. doi: 10.3760/cma.j.issn.0578-1310.2016.03.010. Epub
[PubMed PMID: 26957067]
[90]
Giang H, Nguyen VT, Nguyen SD, Nguyen HP, Vo BT, Nguyen TM, Nguyen NH, Truong KD, Do TT, Phan MD, Nguyen HN. Detection of a heterozygous germline APC mutation in a three-generation family with familial adenomatous polyposis using targeted massive parallel sequencing in Vietnam. BMC medical genetics. 2018 Oct 19:19(1):188. doi: 10.1186/s12881-018-0701-y. Epub 2018 Oct 19
[PubMed PMID: 30340471]
[91]
Sample DC, Samadder NJ, Pappas LM, Boucher KM, Samowitz WS, Berry T, Westover M, Nathan D, Kanth P, Byrne KR, Burt RW, Neklason DW. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC gastroenterology. 2018 Jul 16:18(1):115. doi: 10.1186/s12876-018-0841-8. Epub 2018 Jul 16
[PubMed PMID: 30012100]
[92]
Kallenberg FGJ, Bastiaansen BAJ, Nio CY, Soeters MR, Boermeester MA, Aalfs CM, Bossuyt PMM, Dekker E. Adrenal Lesions in Patients With (Attenuated) Familial Adenomatous Polyposis and MUTYH-Associated Polyposis. Diseases of the colon and rectum. 2017 Oct:60(10):1057-1064. doi: 10.1097/DCR.0000000000000809. Epub
[PubMed PMID: 28891849]
[93]
Klančar G, Blatnik A, Šetrajčič Dragoš V, Vogrič V, Stegel V, Blatnik O, Drev P, Gazič B, Krajc M, Novaković S. A Novel Germline MLH1 In-Frame Deletion in a Slovenian Lynch Syndrome Family Associated with Uncommon Isolated PMS2 Loss in Tumor Tissue. Genes. 2020 Mar 18:11(3):. doi: 10.3390/genes11030325. Epub 2020 Mar 18
[PubMed PMID: 32197529]
[94]
Mittendorf KF, Ukaegbu C, Gilmore MJ, Lindberg NM, Kauffman TL, Eubanks DJ, Shuster E, Allen J, McMullen C, Feigelson HS, Anderson KP, Leo MC, Hunter JE, Sasaki SO, Zepp JM, Syngal S, Wilfond BS, Goddard KAB. Adaptation and early implementation of the PREdiction model for gene mutations (PREMM(5)™) for lynch syndrome risk assessment in a diverse population. Familial cancer. 2022 Apr:21(2):167-180. doi: 10.1007/s10689-021-00243-3. Epub 2021 Mar 23
[PubMed PMID: 33754278]
[95]
Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S. Development and Validation of the PREMM(5) Model for Comprehensive Risk Assessment of Lynch Syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 1:35(19):2165-2172. doi: 10.1200/JCO.2016.69.6120. Epub 2017 May 10
[PubMed PMID: 28489507]
Level 1 (high-level) evidence
[96]
Cox VL, Saeed Bamashmos AA, Foo WC, Gupta S, Yedururi S, Garg N, Kang HC. Lynch Syndrome: Genomics Update and Imaging Review. Radiographics : a review publication of the Radiological Society of North America, Inc. 2018 Mar-Apr:38(2):483-499. doi: 10.1148/rg.2018170075. Epub
[PubMed PMID: 29528821]
[97]
Walkowska J, Kallemose T, Jönsson G, Jönsson M, Andersen O, Andersen MH, Svane IM, Langkilde A, Nilbert M, Therkildsen C. Immunoprofiles of colorectal cancer from Lynch syndrome. Oncoimmunology. 2019:8(1):e1515612. doi: 10.1080/2162402X.2018.1515612. Epub 2018 Sep 26
[PubMed PMID: 30546958]
[98]
McGee SF, AlGhareeb W, Ahmad CH, Armstrong D, Babak S, Berry S, Biagi J, Booth C, Bossé D, Champion P, Colwell B, Finn N, Goel R, Gray S, Green J, Harb M, Hyde A, Jeyakumar A, Jonker D, Kanagaratnam S, Kavan P, MacMillan A, Muinuddin A, Patil N, Porter G, Powell E, Ramjeesingh R, Raza M, Rorke S, Seal M, Servidio-Italiano F, Siddiqui J, Simms J, Smithson L, Snow S, St-Hilaire E, Stuckless T, Tate A, Tehfe M, Thirlwell M, Tsvetkova E, Valdes M, Vickers M, Virik K, Welch S, Marginean C, Asmis T. Eastern Canadian Colorectal Cancer Consensus Conference 2017. Current oncology (Toronto, Ont.). 2018 Aug:25(4):262-274. doi: 10.3747/co.25.4083. Epub 2018 Aug 14
[PubMed PMID: 30111967]
Level 3 (low-level) evidence
[99]
Mocellin S, Baretta Z, Roqué I Figuls M, Solà I, Martin-Richard M, Hallum S, Bonfill Cosp X. Second-line systemic therapy for metastatic colorectal cancer. The Cochrane database of systematic reviews. 2017 Jan 27:1(1):CD006875. doi: 10.1002/14651858.CD006875.pub3. Epub 2017 Jan 27
[PubMed PMID: 28128439]
Level 1 (high-level) evidence
[100]
Snyder M, Bottiglieri S, Almhanna K. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer. Reviews on recent clinical trials. 2018:13(2):139-149. doi: 10.2174/1574887113666180328104109. Epub
[PubMed PMID: 29595113]
[101]
Chen D, Li L, Zhang X, Gao G, Shen L, Hu J, Yang M, Liu B, Qian X. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Medicine. 2018 Mar:97(10):e0097. doi: 10.1097/MD.0000000000010097. Epub
[PubMed PMID: 29517682]
Level 2 (mid-level) evidence
[102]
Caux F, Plauchu H, Chibon F, Faivre L, Fain O, Vabres P, Bonnet F, Selma ZB, Laroche L, Gérard M, Longy M. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. European journal of human genetics : EJHG. 2007 Jul:15(7):767-73
[PubMed PMID: 17392703]
[103]
Won HS, Chang ED, Na SJ, Whang IY, Lee DS, You SH, Kim YS, Kim JS. PTEN Mutation Identified in Patient Diagnosed with Simultaneous Multiple Cancers. Cancer research and treatment. 2019 Jan:51(1):402-407. doi: 10.4143/crt.2017.579. Epub 2018 Feb 27
[PubMed PMID: 29510612]
[104]
Pal R, Bhattacharjee R, Bhansali A. Protean manifestations of Proteus syndrome. Postgraduate medical journal. 2018 Jul:94(1113):416. doi: 10.1136/postgradmedj-2018-135731. Epub 2018 Apr 6
[PubMed PMID: 29626058]
[105]
Tian X, Wang Q, Cai W. A Novel Mutation in MYH Gene Associated with Aggressive Colorectal Cancer in a Child: A Case Report and Review of Literature. OncoTargets and therapy. 2020:13():8557-8565. doi: 10.2147/OTT.S259587. Epub 2020 Aug 25
[PubMed PMID: 32904697]
Level 3 (low-level) evidence
[106]
Maeda T, Cannom RR, Beart RW Jr, Etzioni DA. Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Mar 1:28(7):1175-80. doi: 10.1200/JCO.2009.25.9812. Epub 2010 Feb 1
[PubMed PMID: 20124166]
[107]
Schneider R, Schneider C, Büttner R, Reinacher-Schick A, Tannapfel A, Fürst A, Rüschoff J, Jakobeit C, Royer-Pokora B, Möslein G. [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm]. Zentralblatt fur Chirurgie. 2015 Dec:140(6):591-9. doi: 10.1055/s-0034-1368480. Epub 2014 Nov 5
[PubMed PMID: 25372301]
[108]
Herzig DO, Buie WD, Weiser MR, You YN, Rafferty JF, Feingold D, Steele SR. Clinical Practice Guidelines for the Surgical Treatment of Patients With Lynch Syndrome. Diseases of the colon and rectum. 2017 Feb:60(2):137-143. doi: 10.1097/DCR.0000000000000785. Epub
[PubMed PMID: 28059909]
Level 1 (high-level) evidence
[109]
Dominguez-Valentin M, Seppälä TT, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W, Vangala D, Perne C, Strauß HG, Tecklenburg J, Holinski-Feder E, Steinke-Lange V, Mecklin JP, Plazzer JP, Pineda M, Navarro M, Vidal JB, Kariv R, Rosner G, Piñero TA, Gonzalez ML, Kalfayan P, Sampson JR, Ryan NAJ, Evans DG, Møller P, Crosbie EJ. Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. Journal of clinical medicine. 2020 Jul 18:9(7):. doi: 10.3390/jcm9072290. Epub 2020 Jul 18
[PubMed PMID: 32708519]
Level 2 (mid-level) evidence
[110]
Kalady MF, Church JM. Prophylactic colectomy: Rationale, indications, and approach. Journal of surgical oncology. 2015 Jan:111(1):112-7. doi: 10.1002/jso.23820. Epub 2014 Nov 21
[PubMed PMID: 25418116]
[111]
Yamadera M, Ueno H, Kobayashi H, Konishi T, Ishida F, Yamaguchi T, Hinoi T, Inoue Y, Kanemitsu Y, Tomita N, Ishida H, Sugihara K. Current status of prophylactic surgical treatment for familial adenomatous polyposis in Japan. Surgery today. 2017 Jun:47(6):690-696. doi: 10.1007/s00595-016-1431-4. Epub 2016 Oct 21
[PubMed PMID: 27770209]
[112]
Kennelly RP, Gryfe R, Winter DC. Familial colorectal cancer: Patient assessment, surveillance and surgical management. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2017 Feb:43(2):294-302. doi: 10.1016/j.ejso.2016.07.008. Epub 2016 Jul 27
[PubMed PMID: 27546013]
[113]
Wang X, Yu Y, Meng W, Jiang D, Deng X, Wu B, Zhuang H, Wang C, Shen Y, Yang L, Zhu H, Cheng K, Zhao Y, Li Z, Qiu M, Gou H, Bi F, Xu F, Zhong R, Bai S, Wang Z, Zhou Z. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018 Nov:129(2):300-305. doi: 10.1016/j.radonc.2018.08.027. Epub 2018 Oct 28
[PubMed PMID: 30381141]
Level 2 (mid-level) evidence
[114]
Yu J, Li N, Tang Y, Wang X, Tang Y, Wang SL, Song YW, Liu YP, Li YX, Jin J. Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases. Journal of surgical oncology. 2019 Mar:119(4):532-538. doi: 10.1002/jso.25361. Epub 2019 Jan 4
[PubMed PMID: 30609038]
[115]
Lee SY, Kim DW, Kang SI, Ihn MH, Oh HK, Kang SB, Kim CH, Kim HR, Kim YJ, Ju JK. Impact of Family History on Prognosis of Patients with Sporadic Colorectal Cancer. Annals of surgical oncology. 2019 Apr:26(4):1118-1126. doi: 10.1245/s10434-019-07179-0. Epub 2019 Jan 25
[PubMed PMID: 30684157]
[116]
Thong MSY, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, Holleczek B, Waldeyer-Sauerland M, Waldmann A, Zeissig SR, Brenner H, Arndt V. Age-specific health-related quality of life in long-term and very long-term colorectal cancer survivors versus population controls - a population-based study(). Acta oncologica (Stockholm, Sweden). 2019 May:58(5):801-810. doi: 10.1080/0284186X.2018.1557340. Epub 2019 Feb 8
[PubMed PMID: 30736716]
Level 2 (mid-level) evidence
[117]
Vanaclocha-Espi M, Ibáñez J, Molina-Barceló A, Valverde-Roig MJ, Pérez E, Nolasco A, de la Vega M, de la Lastra-Bosch ID, Oceja ME, Espinàs JA, Font R, Pérez-Riquelme F, Arana-Arri E, Portillo I, Salas D, CRIBEA Group. Risk factors for severe complications of colonoscopy in screening programs. Preventive medicine. 2019 Jan:118():304-308. doi: 10.1016/j.ypmed.2018.11.010. Epub 2018 Nov 8
[PubMed PMID: 30414944]
[118]
Carlomagno N, Santangelo ML, Amato B, Calogero A, Saracco M, Cremone C, Miranda A, Dodaro C, Renda A. Total colectomy for cancer: analysis of factors linked to patients' age. International journal of surgery (London, England). 2014:12 Suppl 2():S135-S139. doi: 10.1016/j.ijsu.2014.08.363. Epub 2014 Aug 30
[PubMed PMID: 25181631]
[119]
Patel SG, Ahnen DJ. Colorectal Cancer in the Young. Current gastroenterology reports. 2018 Mar 28:20(4):15. doi: 10.1007/s11894-018-0618-9. Epub 2018 Mar 28
[PubMed PMID: 29616330]
[120]
Nimptsch K, Wu K. Is Timing Important? The Role of Diet and Lifestyle during Early Life on Colorectal Neoplasia. Current colorectal cancer reports. 2018 Feb:14(1):1-11. doi: 10.1007/s11888-018-0396-7. Epub 2018 Jan 18
[PubMed PMID: 30140177]
[121]
LaDuca H, McFarland R, Gutierrez S, Yussuf A, Ho N, Pepper J, Reineke P, Cain T, Blanco K, Horton C, Dolinsky JS. Quality of Clinician-Reported Cancer History When Ordering Genetic Testing. JCO clinical cancer informatics. 2018 Dec:2():1-11. doi: 10.1200/CCI.18.00014. Epub
[PubMed PMID: 30652589]
Level 2 (mid-level) evidence
[122]
Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Molecular oncology. 2019 Feb:13(2):109-131. doi: 10.1002/1878-0261.12417. Epub 2018 Dec 22
[PubMed PMID: 30520562]
[123]
Weinberg BA, Marshall JL. Colon Cancer in Young Adults: Trends and Their Implications. Current oncology reports. 2019 Jan 18:21(1):3. doi: 10.1007/s11912-019-0756-8. Epub 2019 Jan 18
[PubMed PMID: 30659375]
[124]
Yurgelun MB, Hampel H. Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2018 May 23:38():101-109. doi: 10.1200/EDBK_208341. Epub
[PubMed PMID: 30231390]
Level 3 (low-level) evidence
[125]
Biller LH, Syngal S, Yurgelun MB. Recent advances in Lynch syndrome. Familial cancer. 2019 Apr:18(2):211-219. doi: 10.1007/s10689-018-00117-1. Epub
[PubMed PMID: 30627969]
Level 3 (low-level) evidence
[126]
Barrow P, Khan M, Lalloo F, Evans DG, Hill J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. The British journal of surgery. 2013 Dec:100(13):1719-31. doi: 10.1002/bjs.9316. Epub
[PubMed PMID: 24227356]
Level 1 (high-level) evidence
[127]
Coelho H, Jones-Hughes T, Snowsill T, Briscoe S, Huxley N, Frayling IM, Hyde C. A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome. BMC cancer. 2017 Dec 8:17(1):836. doi: 10.1186/s12885-017-3820-5. Epub 2017 Dec 8
[PubMed PMID: 29221446]
Level 1 (high-level) evidence
[128]
Liang J, Lin C, Hu F, Wang F, Zhu L, Yao X, Wang Y, Zhao Y. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. American journal of epidemiology. 2013 Jun 1:177(11):1169-79. doi: 10.1093/aje/kws382. Epub 2013 Apr 10
[PubMed PMID: 23576677]
Level 1 (high-level) evidence
[129]
Liang TJ, Wang HX, Zheng YY, Cao YQ, Wu X, Zhou X, Dong SX. APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review. Oncotarget. 2017 Jul 11:8(28):46468-46479. doi: 10.18632/oncotarget.17576. Epub
[PubMed PMID: 28515349]
Level 1 (high-level) evidence
[130]
Wakeman C, Keenan J, Eteuati J, Hollington P, Eglinton T, Frizelle F. Chemoprevention of colorectal neoplasia. ANZ journal of surgery. 2017 Dec:87(12):E228-E232. doi: 10.1111/ans.13392. Epub 2015 Dec 21
[PubMed PMID: 26686322]
[131]
Dicks E, Pullman D, Kao K, MacMillan A, Simmonds C, Etchegary H. Universal tumor screening for Lynch syndrome: perspectives of Canadian pathologists and genetic counselors. Journal of community genetics. 2019 Jul:10(3):335-344. doi: 10.1007/s12687-018-0398-9. Epub 2018 Nov 21
[PubMed PMID: 30465127]
Level 3 (low-level) evidence
[132]
Gaitanidis A, Spathakis M, Tsalikidis C, Alevizakos M, Tsaroucha A, Pitiakoudis M. Risk factors for cardiovascular mortality in patients with colorectal cancer: a population-based study. International journal of clinical oncology. 2019 May:24(5):501-507. doi: 10.1007/s10147-018-01382-x. Epub 2019 Jan 2
[PubMed PMID: 30604158]
[133]
Wang J, Luo L, Wang D, Guo B, Li J, Yang Z, Tang D. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis. Journal of cellular biochemistry. 2018 Feb:119(2):1521-1537. doi: 10.1002/jcb.26312. Epub 2017 Nov 24
[PubMed PMID: 28771807]
Level 1 (high-level) evidence
[134]
da Silva WC, de Araujo VE, Lima EMEA, Dos Santos JBR, Silva MRRD, Almeida PHRF, de Assis Acurcio F, Godman B, Kurdi A, Cherchiglia ML, Andrade EIG. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2018 Dec:32(6):585-606. doi: 10.1007/s40259-018-0322-1. Epub
[PubMed PMID: 30499082]
Level 2 (mid-level) evidence
[135]
Jayedi A, Emadi A, Shab-Bidar S. Dietary Inflammatory Index and Site-Specific Cancer Risk: A Systematic Review and Dose-Response Meta-Analysis. Advances in nutrition (Bethesda, Md.). 2018 Jul 1:9(4):388-403. doi: 10.1093/advances/nmy015. Epub
[PubMed PMID: 30032224]
Level 3 (low-level) evidence
[136]
Ma Y, Hu M, Zhou L, Ling S, Li Y, Kong B, Huang P. Dietary fiber intake and risks of proximal and distal colon cancers: A meta-analysis. Medicine. 2018 Sep:97(36):e11678. doi: 10.1097/MD.0000000000011678. Epub
[PubMed PMID: 30200062]
Level 1 (high-level) evidence
[137]
Gianfredi V, Salvatori T, Villarini M, Moretti M, Nucci D, Realdon S. Is dietary fibre truly protective against colon cancer? A systematic review and meta-analysis. International journal of food sciences and nutrition. 2018 Dec:69(8):904-915. doi: 10.1080/09637486.2018.1446917. Epub 2018 Mar 8
[PubMed PMID: 29516760]
Level 1 (high-level) evidence